This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Market Morning: Another 'Merkozy' Meeting

NEW YORK (TheStreet) -- U.S. stock futures were flat early Monday ahead of the latest meeting of "Merkozy" -- German Chancellor Angela Merkel and French President Nicolas Sarkozy are meeting to discuss ways to boost growth as debt fears in the eurozone once again linger.

European stocks were higher, getting a boost from a rise in German exports.

Asian stocks finished higher Monday. The benchmark Shanghai Composite Index gained 2.9% to 2,225.89, while the Hang Seng in Hong Kong rose 1.5%. Markets in Japan were closed.

U.S. stocks finished last week, the first trading week of 2012, with solid gains. The Dow Jones Industrial Average on Friday settled down 56 points, or 0.5%, to 12,360 but posted a gain of more than 1% for the week.

The S&P 500 dropped 3 points, or 0.3%, to 1,278, putting the index 1.6% ahead for the week. The Nasdaq tacked on 4 points, or 0.2%, to 2,674 on Friday, and posted a 2.7% gain for the week.


The economic calendar in the U.S. includes the Conference Board's employment trend index for December at 10 a.m. EST. The Federal Reserve is scheduled to issue consumer credit data at 3 p.m.


Alcoa (AA) posts results after the closing bell Monday, marking the unofficial start to the earnings season.

The aluminum maker last week said its global smelting capacity will be reduced by 12% after the closure of certain plants. Alcoa said it would record fourth-quarter restructuring charges of $155 million to $165 million.

Analysts' expectations on Alcoa's results vary from a loss of 5 cents a share to a profit of 1 cent.


Bristol-Myers Squibb (BMY) plans to acquire Inhibitex (INHX) for $2.5 billion.

Bristol-Myers' all-cash tender offer values Inhibitex at $26 a share, or more than two-and-a-half times the company's closing stock price on Friday of $9.87.

For all that cash, Bristol-Myers gains control of Inhibitex's INX-189, a pill in phase II studies which has the potential to become a component in the first all-oral therapies against hepatitis C.


-- Written by Joseph Woelfel



>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,824.71 -87.40 -0.52%
S&P 500 1,965.85 -4.10 -0.21%
NASDAQ 4,450.7160 +8.0180 0.18%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs